On Thursday, the U.S. market saw a positive trend in the shares of Glaukos Corporation (NYSE: GKOS), which saw a significant rise of 6.92% and conclude the trading day at $85.11. The upward trend in GKOS shares might be linked to an upgrade that was released by analysts the previous day.
The renowned research company JP Morgan gave Glaukos (GKOS) an upgraded rating on Thursday. Analyst firm raised its price target for GKOS from $66 to $91, and upgraded its rating for the stock from “Neutral” to “Overweight”.
Glaukos also said that it will be attending the 42nd Annual J.P. Morgan Healthcare Conference, which will take place in San Francisco, California, on Tuesday, January 9, 2024, at 5:15 p.m. PT.
Furthermore, GKOS’s New Drug Application (NDA) for iDose TR (travoprost intracameral implant) 75 mcg was recently approved by the FDA in the United States. This prostaglandin analog is intended to lower intraocular pressure (IOP) in individuals suffering from open-angle glaucoma (OAG) or ocular hypertension (OHT). It is given as a single dosage per eye.
A unique formulation of travoprost is delivered to the eye in a sustained therapeutic level with iDose TR, an innovative extended-duration intracameral pharmacological therapy. By addressing persistent side effects and patient noncompliance with typical topical glaucoma treatments, the goal is to improve the quality of therapy.
With the FDA’s approval of iDose TR, GKOS has reached a major turning point in its long and inventive history, which began nearly 15 years ago. With its approval, a new era in interventional glaucoma care has begun, offering patients a proactive and dependable method.
According to Glaukos, iDose TR represents a revolutionary medical innovation that might completely alter the way people with open-angle glaucoma and ocular hypertension are treated in the United States.
GKOS is committed to provide cutting-edge treatments for long-term eye conditions, and it thinks iDose TR has the potential to significantly improve the care that Americans with open-angle glaucoma and ocular hypertension get.
